Compare Citius Pharmaceuticals Inc (CTXR) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs NRG Energy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while NRG Energy Inc trades at $107.97 (market cap $22.35B). The key difference: NRG Energy Inc is far larger — about 1641× Citius Pharmaceuticals Inc's market cap, and NRG Energy Inc pays a 1.79% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and NRG Energy Inc for 63 Days on average.
| CTXR | NRG | |
|---|---|---|
Market Cap | $13.62M | $22.35B |
Volume | 132,438 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $1.82 | $184.03 |
52-Week Low | $0.48 | $95.23 |
Typical Hold Time | 17 Days | 63 Days |
Enterprise Value | $3.79M | $46.30B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
NRG Energy trades at $106.32, down 2.11% today, with a bullish technical signal and strong analyst support. The stock shows mixed earnings performance with recent misses but maintains solid fundamentals including $30.71B revenue and 2.56% net margin. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant, positioning for growth in energy infrastructure.
Outlook remains positive with 70% analyst buy ratings and $202.90 consensus price target representing 91% upside. Key risks include execution of major capital projects, debt levels at 56.42% of assets, and energy market volatility. The dividend yield of approximately 1.6% provides income support while growth initiatives drive long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
